Skip to content

Medical emergency? What to do

Generic Breast Cancer Drugs Boost Adherence

3-RXPublished December 16, 20134 min read

Key points

  • The introduction of cheaper, generic aromatase inhibitors, used to prevent breast cancer recurrence, appears to have improved adherence, a researcher said here.
  • But the lower-priced generics had smaller copayments and adherence was greater than for brand name products, Hershman reported at the annual San Antonio Breast Cancer Symposium here.
  • Indeed, the study implies that reducing costs might improve adherence to therapy with aromatase inhibitors (AIs), commented Claudine Isaacs, MD, of Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C., who was not part of the study.
  • "We know that many women either do not initiate or discontinue their highly effective endocrine therapy," she said.

The introduction of cheaper, generic aromatase inhibitors, used to prevent breast cancer recurrence, appears to have improved adherence, a researcher said here.

In an analysis of pharmacy claims data, adherence to hormone therapy varied depending on the copayment required, according to Dawn Hershman, MD, of Columbia University in New York City.

But the lower-priced generics had smaller copayments and adherence was greater than for brand name products, Hershman reported at the annual San Antonio Breast Cancer Symposium here.

The findings suggest that efforts should be directed toward reducing financial constraints on patients, as a matter of public health policy, Hershman argued.

Indeed, the study implies that reducing costs might improve adherence to therapy with aromatase inhibitors (AIs), commented Claudine Isaacs, MD, of Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C., who was not part of the study.

"The use of generic AIs was associated with a significant increase in adherence to and lowering in rate of discontinuation of AI," she told MedPage Today by email.

"We know that many women either do not initiate or discontinue their highly effective endocrine therapy," she said.

The study, she added, suggests "there are a number of encouraging ways to increase consistent use of this highly active therapy."

Hershman and colleagues looked at prescriptions for hormonal therapy, including brand name and generic aromatase inhibitors and tamoxifen, both before and after the 2010 introduction of generic aromatase inhibitors.

All told, they had records for 13,522 patients, including 7,532 who never changed medications and 5,990 who switched at least once, Hershman said.

Of the switchers, 72.9% changed from a brand-name aromatase inhibitor to a generic, she added.

On average, the copayment cost was about $8 for a month's supply of tamoxifen, about $9 for a generic aromatase inhibitor, and about $33 for a brand-name drug.

In the pre-generic era, about 45% of patients started on tamoxifen and the remainder started on a brand-name aromatase inhibitor.

After 2010, the tamoxifen proportion remained stable, at 42.6%, while the generics and brand-name aromatase inhibitors had 38.3% and 19.1% "market share" respectively.

In a multivariate analysis, with the brand-name drugs as the reference, those taking generic drugs were significantly less likely to stop therapy. The hazard ratio was 0.62 and was significant at P<0.001. The likelihood of stopping tamoxifen therapy was the same as that for brand-name aromatase inhibitors, Hershman reported.

The same analysis showed that the likelihood of stopping therapy rose significantly as the copayment rose from below $10 to greater than $20.

A similar analysis showed that adherence to therapy - compared with the brand-name aromatase inhibitors - was greater with the generics and lower with tamoxifen.

The hazard ratios were 1.37 and 0.68, respectively, and were significant at P<0.01 and P<0.001.

Adherence was also lower with higher copayments and higher with greater income, Hershman said.

She cautioned that the study covered only the first 2 years after the introduction of the generic drugs, there was no information on tumor characteristics, and adherence was measured by refills, not pill counts.

Nonetheless, she argued, "out-of-pocket costs are independently associated with adherence and discontinuation," as are generic aromatase inhibitors.

The study was supported by the Breast Cancer Research Foundation, the American Cancer Society, and the National Cancer Institute.

Hershman said she had no disclosures.

Isaacs said she had no disclosures.

###

Primary source: San Antonio Breast Cancer Symposium
Source reference: Hershman DL, et al "The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early stage breast cancer" SABCS 20131; Abstract S3-04.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Keep reading

Brain

Italy court ruling links mobile phone use to tumor

Italy's supreme court has upheld a ruling that said there was a link between a business executive's brain tumor and his heavy mobile phone usage, potentially opening the door to further legal claims. The court's…

2 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.